1 / 20

EFSA Margin of Exposure Approach

EFSA Margin of Exposure Approach. Susan Barlow EFSA Scientific Committee. EFSA OPINION. BACKGROUND TO THE EFSA OPINION. What are the possible approaches for risk assessment of genotoxic carcinogens ingested in low amounts?

Télécharger la présentation

EFSA Margin of Exposure Approach

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. EFSAMargin of Exposure Approach Susan Barlow EFSA Scientific Committee

  2. EFSA OPINION

  3. BACKGROUND TO THE EFSA OPINION • What are the possible approachesfor risk assessment of genotoxic carcinogens ingested in low amounts? • How should the outcomes of the various approaches be interpretedin terms of risks to human health? • To what extent do the approaches available meet the needs of risk managers? • e.g. Do they give practical optionsin situations where exposure cannot be completely eliminated and the magnitude of risk cannot be readily determined? • Do they enable prioritiesfor risk management actions to be set?

  4. WHAT ARE THE POSSIBLE APPROACHES? • ALARA – as low as reasonably achievable • TTC – the threshold of toxicological concern • Dose-response modelling/Numerical calculation of range of risk – by linear low-dose extrapolation • Dose-response modelling/MOE – margin of exposure

  5. ALARA • Needs only hazard identification data (animal or human) • Widely used • Scientifically supportable • Clearly a protective option BUT • Does not make use of all the data (e.g. potency, exposure) • Not helpful for gauging magnitude of risks in relation to exposures (urgency, extent of RM measures needed) • Not helpful for prioritising risks to be managed

  6. TTC • Needs no toxicological data • Does need good exposure data (or worst case scenario) • Coming into use for very low level contaminants BUT • Very low TTC value for potentially genotoxic substances (0.15µg/day) • Not suitable for extremely potent carcinogens (e.g. aflatoxins, azoxy, nitrosamines)

  7. LINEAR EXTRAPOLATION • Provides quantitative upper bound estimate of risk (very conservative) • Widely used BUT • How uncertain are the estimates? • Estimates very model-dependent • Can be misunderstood and misused

  8. MOE • Pragmatic approach that uses both potency and human exposure data • Does not extrapolate below range of observations • Can be complementary to other approaches • Useful as one input to the whole RA process BUT ......

  9. DERIVING THE MOE • Select cancer data set(s) to be used • Traditional approach using NOAELs not appropriate for DNA-reactive substances (cannot infer thresholds) • Use mathematical and statistical modelling to fit best curve to the data in the observed range • Define a benchmark response (e.g. 10% increase in tumour incidence compared to background) and derive corresponding benchmark dose (e.g. BMD10) • To take account of uncertainties in BMD, use lower 95% confidence interval on BMD as reference point or point of departure (e.g. BMDL10)

  10. DERIVING THE MOE: BMD APPROACH BMD10 10% Response = BMR Model fitted to data points BMDL10 Lower 95% confidence interval on dose giving a 10% response

  11. CALCULATING THE MOE BMDL10 MOE = ______________ Human exposure

  12. RECOMMENDATIONS FROM 2005 EFSA/WHO/ILSI CONFERENCE • Need for criteria to assess the quality/adequacy of data for MOE approach(EFSA) • Guidance on dose-response modelling, derivation of Reference Point (WHO, EFSA) • Guidance on explanation and communication of uncertainties (EFSA) • Consider ranges of MOE rather than single values • Consider how to band MOEs with respect to levels of concern (to reduce misinterpretation) • Develop example case studies on specific substances (ILSI)

  13. Published papers from 2005 EFSA/WHO/ILSI Conference

  14. APPLICATION OF THE MOE APPROACH • BY JECFA • Acrylamide (64th M February 2005) • 1,3-dichloro-2-propanol (67th M June 2006) • Ethyl carbamate (64th M February 2005) • PAHs (64th M February 2005) • By EFSA • Aflatoxins (CONTAM Panel January 2007) • Ethyl carbamate (CONTAM Panel Sept 2007) • PAHs (CONTAM Panel June 2008)

  15. USE OF MOE APPROACH BY EFSA Ethyl carbamate in food and beverages • Animal cancer bioassay data • Reference point: BMDL10 • 3 exposure scenarios • Whole population • Consumers of alcoholic beverages • 95th percentile of consumers of alcoholic beverages MoE=18 000MoE=5 000MoE=600

  16. USE OF MOE APPROACH BY EFSA Polycyclic Aromatic Hydrocarbons in Food • Type of data: 2-year carcinogenicity study on coal tar mixtures • Reference point: BMDL10 • Mean and 97.5th percentile exposure to benzo-α-pyrene, PAH2, PAH4 & PAH8

  17. USE OF MOE APPROACH BY EFSA Aflatoxins in almonds, hazelnuts, pistachios and derived products • Type of data: - rat carcinogenicity study - human epi data (chronic hepatitis B) • Reference point: - BMDL10 A (animal data) - BMDL10 H and BMDL1 H (human data) ALARA recommended

  18. JECFA COMPARISON OF SUBSTANCES Daily intake MOE Level of concern Acrylamide 1 g/kg mean 300 of concern 4 g/kg high 75 of concern Ethylcarbamate 15 ng/kg (background) 20,000 low 80 ng/kg (+ alcoholic bev) 3,800 of concern PAHs (benzo[a]pyrene as marker) 4 ng/kg mean 25,000 low 10 ng/kg high 10,000 low DCP 51 ng/kg mean 65,000 low 136 ng/kg high 24,000 low

  19. LIMITATIONS of MOE APPROACH • MOE is a ratio – it does not quantify the risk • Requires good data on food intake and chemical concentration • Risk of misinterpretation – context and characterisation of uncertainties is needed • Assignment of ‘concern levels’ (banding of MOE values) needs further discussion between RAs and RMs

  20. CONCLUSIONS OF EFSA SC 2005 • MOE can be used as a harmonised approach for the RA of genotoxic carcinogens • Can be used to rank and compare substances • Provides RM with a basis for setting priorities for action (and does not exclude applying ALARA) • Use the BMD approach to derive the Reference Point (BMDL10) (If data unsuitable, use T25) • Communicate all assumptions and uncertainties • MOE of 10,000 or higher considered as of low concern

More Related